Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.45 |
| ▸ | REN | P00797 | 8/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17299753 | 0.88 | MAPKAPK2 (0.44) | MAPKAPK2KDM4A | |
| SCHEMBL4696160 | 0.84 | MAPKAPK2 (0.42) | LMNANFKB1BLMPMP22MAPKAPK2 | |
| SCHEMBL15534393 | 0.81 | LMNA (0.59) | LMNANFKB1BLMPMP22 | |
| SCHEMBL31584208 | 0.80 | MAPKAPK2 (0.40) | LMNAMAPKAPK2KDM4A | |
| SCHEMBL24423243 | 0.76 | STK17B (0.50) | LMNAMAPKAPK2KDM4A | |
| SCHEMBL3301163 | 0.75 | KDM4A (0.41) | LMNAMAPKAPK2KDM4A | |
| SCHEMBL30993280 | 0.75 | MAPKAPK2 (0.42) | LMNAMAPKAPK2KDM4A | |
| SCHEMBL10254091 | 0.75 | LMNA (0.54) | LMNANFKB1BLMPMP22 | |
| SCHEMBL31432005 | 0.74 | F2 (0.47) | MAPKAPK2KDM4A | |
| SCHEMBL1900426 | 0.74 | F2 (0.47) | MAPKAPK2KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | LMNA 529/4885NFKB1 1539/4885BLM 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.